Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Gilead Combination Therapy Successful in Phase 2 Trial

September 15, 2010 7:58 am | News | Comments

Gilead Sciences, Inc. announced Phase 2 clinical trial results showing that its investigational "Quad" regimen of elvitegravir, cobicistat and Truvada for the treatment of HIV infection maintained a high rate of virologic suppression through 48 weeks.

TOPICS:

Instruction Manual

September 15, 2010 7:26 am | by Ted Agres, Contributing Editor | Articles | Comments

Biosimilars now have a regulatory pathway, but are the directions to approval clear?

TOPICS:

Next-Generation Sequencing Will Fuel Toxicogenomics Engines

September 15, 2010 7:15 am | by Dr. Jens Hoefkens, Head of Genedata Expressionist | Articles | Comments

A host of new and exciting technologies are providing researchers with an explosion of molecular biological data. Yet, the number of new drugs entering the market is stagnating and about 90% of the compounds entering into preclinical development fail to reach the market.

TOPICS:
Advertisement

Human Genome Sequencing on a Grand Scale

September 15, 2010 6:29 am | by Radoje Drmanac, PhD, Chief Scientific Officer and Co-founder; Complete Genomics, Inc., Mountain View, Calif. | Articles | Comments

Genetic variations—the way in which genes and proteins differ between individuals—can have important medical consequences. As a result, complete human genome sequencing has many potential drug discovery applications.

TOPICS:

NGS Delivers Fundamental Research Shift

September 15, 2010 6:20 am | by Elaine Wong-Ho, Associate Product Marketing Manager; Caliper Life Sciences, Hopkinton, Mass. | Articles | Comments

The three current NGS platforms share a common feature—massively parallel sequencing of spatially separated, clonally amplified DNA molecules. This is fundamentally different than Sanger technology, in which individual sequencing reactions are separated by capillary electrophoresis.

TOPICS:

Personalized Medicine Research Program

September 15, 2010 6:04 am | by Anthony Flynn, Chief Marketing Officer; GenomeQuest, Boston, Mass. | Articles | Comments

Genomic studies combined with individual testing enables researchers to determine a patient's susceptibility to disease, predict how they will respond to a particular drug, and match them with the right therapeutics.

TOPICS:

The Blueprints for Personalized Medicine: A Genome Approach

September 15, 2010 5:50 am | by Edward L. Erickson, President and CEO; BioNanomatrix, Inc., Philadelphia, Pa. | Articles | Comments

Researchers are constantly searching for a better understanding of fundamental disease mechanisms and tools for early diagnosis and even pre-diagnosis of disease.

TOPICS:

Cracking the Code of Mendelian Disease and Cancer

September 15, 2010 5:43 am | by Fred P. Ernani, PhD; SureSelect Platform Business Manager; Agilent Technologies,Santa Clara, Calif. | Articles | Comments

The advent of high-throughput DNA sequencing and the completion of the Human Genome Project was supposed to usher in the era of personalized medicine, where the treatment of disease could be tailored toward one’s genetic predispositions.

TOPICS:
Advertisement

Disposable Bioreactor System

September 14, 2010 8:41 am | Product Releases | Comments

Cellexus Limited offers the CellMaker PLUS single-use disposable bioreactor system, which was designed for efficient growth of the widest range of cell types.

TOPICS:

New Software for PIM Labeling

September 14, 2010 8:27 am | Product Releases | Comments

Virtify, Inc. announced the upcoming release of its new software product Virtify PIM Enterprise, part of the Virtify Enterprise Content Compliance (ECC) Software Suite.

TOPICS:

Ductless Fume Hoods

September 14, 2010 8:19 am | Product Releases | Comments

Air Science has introduced its NEW Purair ECO line of energy-saving ductless fume hoods designed for both chemical and particulate protection over a broad range of laboratory applications. It is available with a choice of controllers.

TOPICS:

FDA Questions Safety, Effectiveness of Lorcaserin

September 14, 2010 8:01 am | by Matthew Perrone, AP Health Writer | News | Comments

Federal health officials said Tuesday that an experimental diet drug produced minimal weight loss while raising safety questions about its effects on the heart, sending shares of its developer Arena Pharmaceuticals plummeting in morning trading.

TOPICS:

Agenebio Awarded ADDF Grant

September 14, 2010 7:51 am | News | Comments

The Alzheimer’s Drug Discovery Foundation has awarded a grant of $244,500 to AgeneBio Inc. to develop a new class of small-molecules that have promise in treating amnestic mild cognitive impairment, a neurological condition that often progresses to Alzheimer’s disease.

TOPICS:

Patent Granted for Stem Cell Therapies

September 14, 2010 7:42 am | News | Comments

Amorcyte, Inc., has been granted the first U.S. patent for a chemotactic hematopoietic stem cell product, its delivery and the cell potency and stability needed to treat the consequences of a vascular injury.

TOPICS:

Genmab, Seattle Genetics Collaborate on Antibody-Drug Conjugate Research

September 14, 2010 7:36 am | News | Comments

Genmab A/S, Copenhagen and Seattle Genetics, Inc. have entered into an antibody-drug conjugate (ADC) research collaboration agreement.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading